Echinocandin Antifungals: How Lipopeptides Break the Fungal Cell Wall

Echinocandins are a class of antifungal drugs that treat serious fungal infections by attacking a structure human cells simply do not have: the fungal cell wall. Their name and their chemistry mark them as peptide-class drugs — they are cyclic lipopeptides, ring-shaped peptides carrying a lipid tail — and understanding how they work explains why they are the first choice for many life-threatening Candida infections.

The target: β-(1,3)-D-glucan synthase

Fungi wrap themselves in a rigid cell wall built largely from a mesh of polysaccharides. A key structural component is β-(1,3)-D-glucan, a long chain of glucose units assembled by an enzyme called β-(1,3)-D-glucan synthase.

Echinocandins inhibit that enzyme. With glucan synthesis blocked, the growing fungus cannot build a sound wall. Under the fungus's own internal osmotic pressure, the weakened wall gives way and the cell bursts. Against many Candida species this is fungicidal (it kills them); against molds like Aspergillus the effect is fungistatic (it halts growth at the growing tips).

Why they are so well tolerated

The reason echinocandins are generally gentle on patients is elegant: human cells have no cell wall and make no β-glucan, so the drug's target does not exist in us. This selective toxicity is a major advantage over some older antifungals that act on the fungal cell membrane (which shares chemistry with human membranes) and can cause more side effects. Echinocandins still have effects to watch — infusion reactions and, for caspofungin, dosing changes in liver impairment — but the class is prized for tolerability.

The members of the class

• Caspofungin (Cancidas) — the first echinocandin. Uses a loading dose; adjusted in moderate liver impairment. Used for invasive candidiasis, esophageal candidiasis, empiric therapy in febrile neutropenia, and salvage treatment of invasive aspergillosis.
• Micafungin (Mycamine) — fixed daily dose; well established for preventing Candida infections in stem-cell transplant recipients.
• Anidulafungin (Eraxis) — uniquely cleared by slow chemical degradation in the blood rather than the liver or kidneys, so no organ-based dose adjustment.
• Rezafungin (Rezzayo) — the newest (2023), engineered from anidulafungin for a very long half-life allowing once-weekly dosing.

Shared strengths and limits

All echinocandins share a common profile:

• Route: intravenous only — they are large molecules not absorbed by mouth.
• First-line for invasive candidiasis: guidelines favor them as initial therapy for most serious Candida infections, especially in sicker patients, after recent azole exposure, or where azole resistance is a concern.
• Poor penetration into the urine and the central nervous system, so they are not used for fungal urinary-tract infections or fungal meningitis — different antifungals (like fluconazole or amphotericin) are needed there.
• Resistance can occur (through mutations in the glucan-synthase target), so treatment is guided by culture and susceptibility testing.

How they fit alongside other antifungals

Antifungal therapy has three broad weapon types: the azoles (like fluconazole, voriconazole) that block cell-membrane sterol synthesis, the polyenes (amphotericin B) that punch holes in the membrane, and the echinocandins that break the cell wall. Because echinocandins hit a wholly different target, they are valuable when azole resistance is present and are sometimes combined with an azole in severe mold infections. For invasive Candida disease, an echinocandin is usually where treatment begins, with step-down to an oral azole once the patient stabilizes.

Echinocandins are prescription hospital medicines used under specialist (often infectious-disease) supervision for serious infections. This page explains the class; it is not medical advice.